Holen Sie sich die Stockscreener-App
24.77
5.95%
1.52
Schlusskurs vom Vortag:
$23.25
Offen:
$23.58
24-Stunden-Volumen:
297.59K
Relative Volume:
0.40
Marktkapitalisierung:
$1.47B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-85.21M
KGV:
-13.11
EPS:
-1.89
Netto-Cashflow:
$-68.53M
1W Leistung:
+58.52%
1M Leistung:
+26.39%
6M Leistung:
+14.15%
1J Leistung:
+2.00%
1-Tages-Spanne:
$23.27
$24.83
1-Wochen-Bereich:
$14.79
$25.59
52-Wochen-Spanne:
$13.30
$25.59
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Firmenname
Enliven Therapeutics Inc
Sektor
Branche
Telefon
720-647-8519
Adresse
6200 LOOKOUT ROAD, BOULDER
Vergleichen Sie ELVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
24.72 | 1.38B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.37 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.29 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
814.78 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.34 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Eingeleitet | Goldman | Buy |
| 2024-12-13 | Eingeleitet | BTIG Research | Buy |
| 2024-09-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-09 | Eingeleitet | Mizuho | Buy |
| 2023-03-29 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars - Sahm
Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging Phase 1b ENABLE Trial Data - Yahoo Finance UK
How Enliven Therapeutics Inc. stock reacts to oil prices2025 Analyst Calls & Long-Term Growth Stock Strategies - ulpravda.ru
What risks investors should watch in Enliven Therapeutics Inc. stockMarket Trend Report & Expert Approved Momentum Trade Ideas - ulpravda.ru
Enliven touts drug trial results, adds pharma exec to board - BizWest
Why Enliven Therapeutics Inc. stock could benefit from AI revolutionMarket Risk Report & Community Shared Stock Ideas - ulpravda.ru
Enliven Therapeutics’ Initial Leukemia Drug Data Excite Investors, Shares Surge - Bitget
Will Enliven Therapeutics Inc. stock see insider buyingWeekly Stock Report & AI Forecasted Stock Moves - ulpravda.ru
Enliven Stock Soars 51% After Positive CML Trial Results - Nasdaq
How supply chain issues affect Enliven Therapeutics Inc. stock2025 Retail Activity & Free Risk Controlled Daily Trade Plans - ulpravda.ru
Shorts Report: How Enliven Therapeutics Inc. stock reacts to oil pricesFed Meeting & Daily Oversold Stock Bounce Ideas - ulpravda.ru
Enliven surges on trial data for leukemia drug (ELVN:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
ELVN Stock Shot Up 60% Today – What’s Driving The Rally? - Stocktwits
How resilient is Enliven Therapeutics Inc. stock in market downturns2025 Volatility Report & Daily Entry Point Trade Alerts - ulpravda.ru
Enliven Stock Soars On Promising Phase 1b Data In Chronic Myeloid Leukaemia - Nasdaq
Enliven reports positive initial phase 1b data for ELVN-001 in CML By Investing.com - Investing.com South Africa
Enliven reports positive initial phase 1b data for ELVN-001 in CML - Investing.com Canada
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones - PR Newswire
Enliven Therapeutics continues to prepare for phase 3 trial initiation in 2026 - MarketScreener
Scott Garland joins Enliven Therapeutics board as company prepares for CML trial - Investing.com Nigeria
Veteran cancer-drug leader joins company pushing new CML drug to Phase 3 - Stock Titan
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Earnings Risk: How Enliven Therapeutics Inc stock reacts to oil prices2025 Sector Review & Daily Chart Pattern Signals - moha.gov.vn
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Avoiding Lag: Real-Time Signals in (ELVN) Movement - Stock Traders Daily
Enliven Therapeutics CSO sells $84k in shares By Investing.com - Investing.com Nigeria
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 5,000 Shares of Stock - MarketBeat
Enliven Therapeutics CSO sells $84k in shares - Investing.com
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 6.1%Here's What Happened - MarketBeat
First Week of February 2026 Options Trading For Enliven Therapeutics (ELVN) - Nasdaq
Portfolio Shifts: Is Enliven Therapeutics Inc. stock near bottom after decline2025 Volatility Report & Daily Entry Point Trade Alerts - moha.gov.vn
Will Enliven Therapeutics Inc. stock benefit from AI adoption2025 Top Decliners & Fast Exit/Entry Strategy Plans - Улправда
Is Enliven Therapeutics Inc. stock near bottom after declineFed Meeting & Free Weekly Watchlist of Top Performers - Улправда
Technical Reactions to ELVN Trends in Macro Strategies - Stock Traders Daily
Is Enliven Therapeutics Inc. stock a buy before product launchesJuly 2025 Volume & Verified Stock Trade Ideas - DonanımHaber
Enliven Therapeutics Earnings Notes - Trefis
Will Enliven Therapeutics Inc. stock gain from strong economy2025 Biggest Moves & Real-Time Buy Zone Alerts - Улправда
Enliven Therapeutics (ELVN) Stock Analysis Report | Financials & Insights - Benzinga
Enliven Therapeutics (NASDAQ: ELVN) registers shares for 2025 equity inducement plan - Stock Titan
Enliven Therapeutics, Inc.Common Stock (NQ: ELVN - Markets Financial Content
VIX Spike: How resilient is Enliven Therapeutics Inc stock in market downturnsQuarterly Trade Report & Risk Managed Investment Signals - moha.gov.vn
5AM Venture Management LLC Reduces Stock Holdings in Enliven Therapeutics, Inc. $ELVN - Defense World
CEO moves at Prolynx, Centessa, Kyowa Kirin, Enliven, Expression - BioCentury
Enliven Therapeutics (ELVN) officer-director discloses no owned securities - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) COO Anish Patel Sells 6,663 Shares of Stock - MarketBeat
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - Nasdaq
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 6.5% Following Insider Selling - MarketBeat
Enliven Therapeutics appoints Rick Fair as new CEO - Investing.com
Enliven Therapeutics, Inc. Announces Management Changes - marketscreener.com
Enliven Therapeutics appoints Rick Fair as new CEO, shares down - TradingView — Track All Markets
Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):